Nova Eye Medical (EYE) Discussion, page-2335

My main point of interest was that the market cap is currently around $50 million and sales were heading in a direction that had a price/sales ratio near 2. I've seen where the average for similar companies is more around 7 or so, so seems undervalued. Also profitability appears not too far down the road. Even with the dilution and any reduced expectations for rate of revenue growth you'd still think this should end up north of 50c within six months.

Now Tom has flagged the need for "boots on the ground" to properly realise growth it may be harder to get the extra revenue without jacking up expenses too. So it was nice to hear they think being cash flow positive is in sight and genuine profis can't be too far away. Also as others have mentioned 2RT could emerge at anytime. So overall still bullish but know its likely tough over the next few weeks.